High-Dose Terazosin Therapy (5mg) in Korean Patients with Lower Urinary Tract Symptoms with or without Concomitant Hypertension: A Prospective, Open-Label Study.
10.3349/ymj.2007.48.6.994
- Author:
Cheol KWAK
1
;
Jeong Ki LEE
;
Ja Hyeon KU
Author Information
1. Department of Urology, Seoul National University College of Medicine, Seoul, Korea. randyku@hanmail.net
- Publication Type:Original Article ; Clinical Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Hypertension;
prostate;
lower urinary tract symptoms;
terazosin
- MeSH:
Adrenergic alpha-Antagonists/adverse effects/therapeutic use;
Aged;
Asian Continental Ancestry Group;
Blood Pressure/drug effects;
Humans;
Hypertension/complications/*drug therapy/physiopathology;
Korea;
Male;
Middle Aged;
Prazosin/adverse effects/*analogs & derivatives/therapeutic use;
Prospective Studies;
Prostate/drug effects/pathology;
Treatment Outcome;
Urodynamics/drug effects;
Urologic Diseases/complications/*drug therapy/ethnology
- From:Yonsei Medical Journal
2007;48(6):994-1000
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We determined the efficacy and safety of a relatively high dose of terazosin (5mg) in Korean patients with lower urinary tract symptoms (LUTS), with or without concomitant hypertension. MATERIALS AND METHODS: From July to December 2006, 200 men who consecutively presented with LUTS were prospectively studied. Eight weeks after treatment, blood pressure (BP), uroflowmetry, and International Prostate Symptom Score (I-PSS) were assessed. For analysis purposes, patients were stratified according to concomitant hypertension. Of the 200 patients, 173 completed the scheduled eight-week treatment period. RESULTS: At baseline, no differences were evident in the two groups in terms of I-PSS, Qmax, PVR and BP. After eight weeks of treatment-although I-PSS and uroflowmetry parameters were not significantly different in the two groups-systolic and diastolic BP in the non-hypertensive control group were higher than in the hypertensive group (p= 0.001 and p=0.0100, respectively). Changes in I-PSS, uroflowmetry parameters, and BPs measured at week eight post- treatment commencement did not significantly differ between the two groups. Moreover, the addition of 5mg of terazosin to antihypertensives did not cause a significant reduction in either systolic or diastolic BP in either group. CONCLUSION: Adding terazosin to existing antihypertensive regimens did not seem to increase the incidence of adverse events. Our findings suggest that 5mg terazosin is effective and that it has an acceptable safety profile as an add-on therapy for patients with LUTS and concomitant hypertension.
